FOLFOXIRI vs FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases and right-sided and/or RAS/BRAFV600E mutated primary tumor: phase III CAIRO5 study. Issue 2 (February 2023) - Bond, Marinde; Bolhuis, Karen; Van Amerongen, Martin; Dejong, Cornelis; Engelbrecht, Marc; Gerhards, Michael; Van Gulik, Thomas; De Jong, Koert; Kazemier, Geert; Klaase, Joost; Liem, Mike; Van Lienden, Krijn; et al.